At the briefing, Dr. Diaz, an oncologist at Johns Hopkins, said that PACE could be used to help clinicians determine who is cured or not cured after surgical resection. “Currently, as physicians we can't tell a patient after breast, colon, or lung cancer surgery whether or not they've been cured,” he commented. “A fraction of these patients will be cured by surgery alone, but many will have residual disease. We hope that PARE will be able to discriminate between those individuals that are cured and those that are not cured by detecting residual disease at first surgery. This approach would thereby spare cured individuals from unnecessary and potentially toxic and harmful chemotherapy.”